11C-PBR28 ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02702102 (ClinicalTrials.gov) | December 2015 | 3/3/2016 | Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies | Imaging Inflammation in Patients With Diffuse Lewy Body Disease | Diffuse Lewy Body Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia | Drug: 11C-PBR28 | William Charles Kreisl | National Institute on Aging (NIA) | Completed | 60 Years | N/A | All | 5 | Phase 2 | United States |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04230174 (ClinicalTrials.gov) | February 2020 | 13/1/2020 | Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation | Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation | Multiple Sclerosis | Drug: 11C-PBR28 | Massachusetts General Hospital | Genentech, Inc. | Not yet recruiting | 18 Years | 65 Years | All | 24 | Phase 4 | NULL |